secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001628280-23-017031
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aadi Bioscience reports Q1 2023 FYARRO sales of $5.9M, net loss $15.2M; PRECISION 1 interim analysis expected end 2023
--------------------------------------------------------------------------------

- FYARRO net product sales $5.9M, up 12% QoQ from $5.2M in Q4 2022 and $2.3M in Q1 2022.
- Net loss $15.2M vs $13.9M in Q1 2022; cash $151.2M expected to fund operations into 2025.
- PRECISION 1 trial enrolling evenly in TSC1/2 arms; >15 tumor types; interim efficacy analysis on 40 patients expected by year-end 2023.
- Appointed Dr. Mohammad Hirmand to board; Phase 1/2 KRAS G12C combo trial with adagrasib expected to start dosing in Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000162828023017031/0001628280-23-017031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000162828023017031/aadi-20230510.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-017031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer